The Swiss voice in the world since 1935

Study finds hydroxychloroquine linked to higher death rate in Covid-19 patients

medicine bottle
The study evaluated 96,000 Covid-19 patients in 671 hospitals worldwide. Copyright 2020 The Associated Press. All Rights Reserved.

A study by the University Hospital of Zurich and Harvard Medical School finds the controversial antimalarial drugs, hydroxychloroquine and a similar drug chloroquine, show no benefit against Covid-19.

According to the studyExternal link published on Friday in the Lancet, hospitalised patients taking a regimen of the antimalarial drugs had a higher mortality rate. Patients treated with one of the drugs had a mortality rate of 11.1%, compared with 9.3% for a control sample.

The study, which was led by researchers at Harvard Medical School and the University Hospital of Zurich, evaluated 96,000 Covid-19 patients in 671 hospitals worldwide. About 15,000 of them were treated with one of the antimalarial drugs with or without antibiotics (macrolides such as azithromycin and clarithromycin) at the onset of the disease.
More

The researchers also observed a four-fold increased risk of cardiac arrhythmia. Some 4-8% of patients treated with one of the antimalarial drugs experienced a new heart arrhythmia, compared to 0.3% for those who were not taking such treatment.

There is “no scientific evidence” of the effectiveness of hydroxychloroquine and chloroquine, said Frank Ruschitzka, head of the Department of Cardiology at the University Hospital of Zurich in a statementExternal link.

“Hydroxychloroquine and chloroquine should therefore no longer be used for Covid-19 before we have the results of further, currently ongoing randomised clinical studies.”

The antimalarial drugs have been surrounded by controversy after enthusiastic remarks by US President Donald Trump earlier this year that left some epidemiologists uneasy given the well-known risks of the drugs particularly for people with heart conditions.

Last week, President Trump indicated that he has been taking hydroxychloroquine as a preventative measure. The US Food and Drug Administration (FDA) granted the drug emergency use authorization earlier this year but European authorities have been less enthusiastic about the drug.

Some of the excitement and hope stemmed from some pre-clinical studies as well as anecdotal evidence that it improved patents’ recovery.

In Switzerland, 17 hospitals are currently participating in a World Health Organization (WHO) solidarity study to test the effectiveness of hydroxychloroquine.

More
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Weekly top stories

Keep up to date with the best stories from SWI swissinfo.ch on a range of topics, straight into your mailbox.

Weekly

The SBC Privacy Policy provides additional information on how your data is processed.


Popular Stories

News

One person consumes 4.8 megawatt hours of electricity

More

One person consumes 4.8 megawatt hours of electricity

This content was published on On average, the Swiss consume 4.8 megawatt hours of electricity per year. According to Velobiz.de, this is roughly equivalent to the amount generated by all 176 cyclists in the Tour de France during the entire race.

Read more: One person consumes 4.8 megawatt hours of electricity
Lisa Mazzone criticises the Federal Council's neo-liberal policy

More

Foreign Affairs

Green party leader criticises government’s neo-liberal policy

This content was published on The Green Party delegates' meeting opened on Saturday morning in Vicques (JU) with a speech by party president Lisa Mazzone. Mazzone took particular aim at the Federal Council's policy towards the United States.

Read more: Green party leader criticises government’s neo-liberal policy
Safra Sarasin and a former asset manager sentenced

More

Swiss Politics

Safra Sarasin private bank and former asset manager sentenced

This content was published on The Office of the Attorney General of Switzerland has fined private bank J. Safra Sarasin CHF3.5 million for aggravated money laundering. A former bank employee received a six-month suspended prison sentence.

Read more: Safra Sarasin private bank and former asset manager sentenced
1MDB affair: JPMorgan to pay CHF 270 million

More

Swiss Politics

JPMorgan to pay CHF270 million to settle 1MDB claims

This content was published on JPMorgan Chase has agreed to pay CHF270 million to the Malaysian government to settle all issues related to its role in the 1MDB financial scandal.

Read more: JPMorgan to pay CHF270 million to settle 1MDB claims
Philippe Lazzarini has overseen UNRWA since 2020.

More

Foreign Affairs

UNRWA boss Lazzarini to step down in March 2026

This content was published on Philippe Lazzarini will step down as head of the United Nations Relief and Works Agency for Palestinian Refugees (UNRWA) at the end of his term in March, he announced on Thursday.

Read more: UNRWA boss Lazzarini to step down in March 2026

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR